Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response. Advances in therapy. [Adv Ther] Journal article | | Title | Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response. | | Author(s) | Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S, Larsson AM | | Institution | IHE, The Swedish Institute for Health Economics, Lund, Sweden. | | Source | Adv Ther 2005 May-Jun; 22(3):208-24. | | MeSH | Adult
Aged
Aged, 80 and over
Anemia
Antineoplastic Agents
Drug Costs
Drug Utilization
Epoetin Alfa
Erythropoietin
Guideline Adherence
Hematinics
Humans
Middle Aged
Practice Guidelines
Research Support, Non-U.S. Gov't
Retrospective Studies
Sweden
Treatment Outcome
| | Abstract | A retrospective chart review was performed at 3 Swedish hospitals to evaluate the utilization, outcomes, and cost of using epoetin alfa or darbepoetin alfa to treat cancer patients with chemotherapy-related anemia. Data on dosage, duration of treatment, hematologic response, red blood cell transfusions, and healthcare resource consumption were collected and analyzed at various time points following the initiation of drug therapy. A significantly faster hematologic response and increase in hemoglobin were observed in patients treated with epoetin alfa. Dosages used in clinical practice appeared to be lower than those recommended by Swedish treatment guidelines. There were no significant differences in resource utilization or healthcare costs between the 2 treatment groups. By day 112, the mean treatment cost per patient, in Swedish kronors (SEK), was SEK74,701 (approximately US$9800 or approximately 8300) with epoetin alfa and SEK85,285 (approximately US$11,000 or approximately 9500) with darbepoetin alfa. Drug acquisition and administration accounted for 81% and 67% of the total cost of epoetin alfa and darbepoetin alfa therapy, respectively; the remainder of the total cost was for hospitalization and transfusions. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 16236682 |
|
|
| |
Advertise on this site.
| | |
|
